0000000000406634

AUTHOR

R. Mitnacht-kraus

showing 3 related works from this author

Preclinical characterization of IMAB362-vcMMAE, an anti-CLDN18.2 antibody–drug conjugate

2017

0301 basic medicineAntibody-drug conjugatebiologybusiness.industryHematologyPharmacology03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisbiology.proteinMedicineAntibodybusinessIMAB362Annals of Oncology
researchProduct

Preclinical characterization of IMAB362 for the treatment of gastric carcinoma

2017

0301 basic medicine03 medical and health sciences030104 developmental biology0302 clinical medicineOncologybusiness.industry030220 oncology & carcinogenesisCancer researchMedicineHematologyGastric carcinomabusinessIMAB362Annals of Oncology
researchProduct

Preclinical evaluation of the anti-CLDN18.2 antibody, IMAB362, in pancreatic carcinoma

2017

0301 basic medicineOncologymedicine.medical_specialtybiologybusiness.industryHematologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisPancreatic cancerInternal medicinebiology.proteinmedicineCA19-9Pancreatic carcinomaAntibodybusinessIMAB362Annals of Oncology
researchProduct